Obésité

, 3:280 | Cite as

Sujets « métaboliquement obèses » de poids normal. Seconde partie: pronostic et prise en charge

Revue Clinique / Clinical Review

Résumé

Les personnes non obèses « métaboliquement anormales » (MONW) sont rarement dépistées en raison d’un poids corporel faussement rassurant. Elles présentent pourtant bon nombre de marqueurs du syndrome métabolique, connus pour être associés à un risque accru de diabète de type 2, de maladies cardiovasculaires et de mortalité. Cet article vise à évaluer les conséquences cliniques auxquelles sont exposées les personnes MONW et à décrire les grands principes de la prise en charge thérapeutique de ce syndrome.

Mots clés

Insulinorésistance MONW Obésité Risque cardiovasculaire Syndrome métabolique 

Metabolically obese normal-weight subjects. Part two: prognosis and management

Abstract

Metabolically obese normal-weight (MONW) individuals are frequently not detected because of a falsely reassuring body weight. However, they have most of the metabolic syndrome markers known to be associated with a higher risk of type 2 diabetes, cardiovascular disease and mortality. The present review paper aims to describe the clinical consequences to which MONW people are exposed and the main principles of managing this syndrome.

Keywords

Cardiovascular risk Insulin resistance Metabolic syndrome MONW Obesity 

Références

  1. 1.
    Beck E, Scheen AJ (2008) Sujets « métaboliquement obèses » de poids normal. Première partie: diagnostic, physiopathologie et prévalence. Obésité 3: 184–193CrossRefGoogle Scholar
  2. 2.
    Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S (1998) The metabolically obese, normal-weight individual revisited. Diabetes 47: 699–713PubMedCrossRefGoogle Scholar
  3. 3.
    Conus F, Rabasa-Lhoret R, Peronnet F (2007) Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab 32: 4–12PubMedCrossRefGoogle Scholar
  4. 4.
    Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444: 875–880PubMedCrossRefGoogle Scholar
  5. 5.
    Després JP, Lemieux I, Bergeron J, et al. (2008) Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28: 1039–1049PubMedCrossRefGoogle Scholar
  6. 6.
    Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28: 2289–2304 and Diabetologia 48: 1684–99PubMedCrossRefGoogle Scholar
  7. 7.
    Meigs JB, Wilson PWF, Fox CS, et al. (2006) Body mass index, metabolic syndrome and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91: 2906–2912PubMedCrossRefGoogle Scholar
  8. 8.
    Katzmarzyk PT, Church TS, Janssen I, et al. (2005) Metabolic syndrome, obesity and mortality. Impact of cardiorespiratory fitness. Diabetes Care 28: 391–397PubMedCrossRefGoogle Scholar
  9. 9.
    Wei M, Kampert JB, Barlow CE, et al. (1999) Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight and obese men. JAMA 282: 1547–1553PubMedCrossRefGoogle Scholar
  10. 10.
    Saint-Pierre AC, Cantin B, Mauriège P, et al. (2005) Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ 172: 1301–1305Google Scholar
  11. 11.
    The DECODE Study Group (2008) Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk? Int J Obes 32: 757–762CrossRefGoogle Scholar
  12. 12.
    Fontbonne AM, Tchobroutsky G, Eschwege E, et al. (1988) Coronary heart disease mortality risk: plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris Prospective Study. Int J Obes 12: 557–565PubMedGoogle Scholar
  13. 13.
    Empana JP, Ducimetière P, Charles MA, Jouven X (2004) Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I. Circulation 110: 2781–2785PubMedCrossRefGoogle Scholar
  14. 14.
    Guize L, Thomas F, Pannier B, et al. (2006) Syndrome métabolique: prévalence, marqueurs de risque associés et mortalité dans une population française de 62 000 sujets. Bull Acad Natl Med 190: 685–700PubMedGoogle Scholar
  15. 15.
    Ford ES (2005) Risks for all-cause mortality, cardiovascular disease and diabetes associated with the metabolic syndrome. A summary of the evidence. Diabetes Care 28: 1769–1778PubMedCrossRefGoogle Scholar
  16. 16.
    Balkau B, Deanfield JE, Després JP, et al. (2007) International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease and diabetes mellitus in 168 000 primary care patients in 63 countries. Circulation 116: 1942–1951PubMedCrossRefGoogle Scholar
  17. 17.
    Yusuf S, Hawken S, Ounpuu S, et al. (2005) Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 366: 1640–1649PubMedCrossRefGoogle Scholar
  18. 18.
    Scheen AJ (2004) Management of the metabolic syndrome. Minerva Endocrinol 29: 31–45PubMedGoogle Scholar
  19. 19.
    Grundy SM, Cleeman JI, Daniels SR, et al. (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 112: 2735–2752PubMedCrossRefGoogle Scholar
  20. 20.
    Lindström J, Ilanne-Parikka P, Peltonen M, et al. (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368: 1673–1679PubMedCrossRefGoogle Scholar
  21. 21.
    Basdevant A, Laville M, Ziegler O (1998) Recommandations pour le diagnostic, la prévention et le traitement des obésités. Diab Metab 24(Suppl 2): 1–48Google Scholar
  22. 22.
    Scheen AJ (2007) Diabetes, obesity and metabolic syndrome. In: Meckling KA (ed) Nutrient-drug interactions. CRC Press Taylor & Francis, Boca Raton, FL, US, pp. 1–30Google Scholar
  23. 23.
    Scheen AJ (2007) Nutritional counseling for overweight patients and patients with metabolic syndrome. In: Perk J, Mathes P, Gohlke H, et al. (eds) Cardiovascular prevention and rehabilitation. Springer-Verlag, London, UK, pp. 201–211CrossRefGoogle Scholar
  24. 24.
    Chiolero A, Faeh D, Paccaud F, Cornuz J (2008) Consequences of smoking for body weight, body fat distribution and insulin resistance. Am J Clin Nutr 87: 801–809PubMedGoogle Scholar
  25. 25.
    Colombo O, Villani S, Pinelli G, et al. (2008) To treat or not to treat: comparison of different criteria used to determine whether weight loss is to be recommended. Nutr J 7: 5 [Epub ahead of print]PubMedCrossRefGoogle Scholar
  26. 26.
    Feldeisen SE, Tucker KL (2007) Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab 32: 46–60PubMedCrossRefGoogle Scholar
  27. 27.
    Esposito K, Ciotola M, Giugliano D (2007) Mediterranean diet and the metabolic syndrome. Mol Nutr Food Res 51: 1268–1274PubMedGoogle Scholar
  28. 28.
    Minich DM, Bland JS (2008) Dietary management of the metabolic syndrome beyond macronutrients. Nutr Rev 66: 429–444PubMedCrossRefGoogle Scholar
  29. 29.
    Scheen AJ, Paquot N (2001) Effets bénéfiques de l’activité physique sur les facteurs de risque cardiovasculaire. Rev Med Liège 56: 239–243PubMedGoogle Scholar
  30. 30.
    Lakka TA, Laaksonen DE (2007) Physical activity in prevention and treatment of the metabolic syndrome. Appl Physiol Nutr Metab 32: 76–88PubMedCrossRefGoogle Scholar
  31. 31.
    Gill JM, Malkova D (2006) Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity. Clin Sci (Lond) 110: 409–25CrossRefGoogle Scholar
  32. 32.
    DuBose KD, Eisenmann JC, Donnelly JE (2007) Aerobic fitness attenuates the metabolic syndrome score in normal-weight, at-risk-for-overweight, and overweight children. Pediatrics 120: e1262–e1268PubMedCrossRefGoogle Scholar
  33. 33.
    Scheen AJ (2008) The future of obesity: new drugs versus lifestyle interventions? Exp Opin Invest Drugs 17: 263–267CrossRefGoogle Scholar
  34. 34.
    Rucker D, Padwal R, Li SK, et al. (2007) Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335: 1194–1199PubMedCrossRefGoogle Scholar
  35. 35.
    Scheen AJ, Paquot N (2007) Pharmacological treatment of obesity, food intake and reversal of metabolic disorders. Curr Nutr Food Sci 3: 123–133CrossRefGoogle Scholar
  36. 36.
    Fontbonne A, Charles MA, Juhan-Vague I, BIGPRO Study Group (1994) The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. Diabetes Care 19: 920–926CrossRefGoogle Scholar
  37. 37.
    Miyazaki Y, Mahankali A, Matsuda M, et al. (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87: 2784–2791PubMedCrossRefGoogle Scholar
  38. 38.
    Bays H, Dujovne CA (2006) Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep 8: 144–156PubMedCrossRefGoogle Scholar

Copyright information

© Springer Paris 2008

Authors and Affiliations

  1. 1.Service de diabétologie, de nutrition et des maladies métaboliques, département de médecineCHU Sart-TilmanLiègeBelgique
  2. 2.Université de LiègeLiègeBelgique
  3. 3.Unité de pharmacologie clinique, département de médecineCHU Sart-TilmanLiègeBelgique

Personalised recommendations